SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 18, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare
Fourth Quarter Revenue Increased 16% to $34.5 Million ; Volume Grew 14% to 13,130 Tests Decipher Acquisition to Expand Global Leadership in Cancer Genomic Diagnostics While Accelerating Growth Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health , Life
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 10, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2020 after the close of market on Wednesday, February 17 .
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 9, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 8,547,297 shares of common stock, including 1,114,864 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74.00 per share.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of $400.0 million in shares of its common stock. All of the shares are being offered by Veracyte .
Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth Tina Nova , Ph.D., Decipher Biosciences’ president and CEO, has left Veracyte’s board and will become
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 3, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced preliminary results for the fourth quarter and full year ended December 31, 2020 . The company expects to report total revenue of between $34.0 million and $35.0 million and product and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
